3 not yet recruiting, 2 recruiting, 2 unknown. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 3, Recruiting 2, Unknown 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow KN026: new trials by email Literature Review of KN026 trials Research Report on KN026
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer SYS6023, KN026 - Advanced Breast Cancer | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 36 | 2026-05-25 | 2026-06-16 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer KN026, Capecitabine, Enlonstobart - HER2-positive Gastric Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 490 | 2025-12-30 | 2026-01-12 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer JSKN003, KN026, Capecitabine - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 153 | 2025-06-15 | 2025-05-31 |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC KN026, KN046, XELOX - HER2-positive Locally Advanced Resectable Gastric Cancer | Phase 2 | Recruiting | Peking University | 18 | 2023-09-22 | 2024-05-10 |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma KN026, KN046, XELOX - HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 80 | 2023-08-15 | 2023-08-21 |
| Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer KN026 - Breast Cancer | Phase 2 | Unknown | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 30 | 2021-08-09 | 2022-06-22 |
| Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer Concurrent chemotherapy and KN026, KN026 monotherapy, KN026 combination - Metastatic Breast Cancer | Phase 2 | Unknown | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 68 | 2019-12-31 | 2023-09-21 |
Breast Neoplasms (2)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (2) · Shanghai JMT-Bio Inc. (2) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Peking University (1) · Peking University Cancer Hospital & Institute (1)
China (5)
Jiong Wu, professor (1) · Qingyuan Zhang, M.D. (1) · Qingyuan Zhang, Professor (1)